Key result
Durable polymer DES yields similar composite outcomes to biodegradable polymer DES in complex PCI.
Why the study?
Comparative data of durable polymer versus biodegradable polymer drug-eluting stents are limited in ACS patients undergoing complex PCI.
Does durable polymer DES compared to biodegradable polymer DES improve clinical outcomes in patients with acute coronary syndrome undergoing complex PCI?
RCT (n=3,301)
1:1
Does durable polymer DES compared to biodegradable polymer DES improve clinical outcomes in patients with acute coronary syndrome undergoing complex PCI?
Hazard Ratio: 0.87 (95% CI 0.57–1.33)
p-value: p=0.522
Durable and biodegradable polymer drug-eluting stents provide similar 12-month clinical outcomes in patients with acute coronary syndrome undergoing complex PCI.
No takes yet. Share an insight, caveat, or question.
Does not support preferring one polymer type in ACS complex PCI; leaves open need for randomized confirmation of equivalence.
Hwang et al. (2022) conducted an RCT in Acute coronary syndrome (n=3,301). Durable polymer drug-eluting stents (DP-DES) vs. Biodegradable polymer drug-eluting stents (BP-DES) was evaluated on Patient-oriented composite outcome (POCO) in complex PCI (HR 0.87, 95% CI 0.57-1.33, p=0.522). In ACS patients undergoing complex PCI, durable polymer DES showed similar risks of patient-oriented composite outcomes compared to biodegradable polymer DES (HR 0.87; 95% CI 0.57-1.33; P=0.522).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: